MedTrace Logo

Interval Training Plus Creatine Effects on Performance and Glucose Tolerance

NCT02370212 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-01-20

No results posted yet for this study

Summary

Recent evidence suggests that high -intensity interval training (HIIT) may be an effective strategy to improve cardiorespiratory fitness, exercise performance, and insulin sensitivity. In addition, creatine (Cr), a nitrogen- containing compound, is widely used to enhance high intensity exercise performance. A seminal study demonstrated that the muscle content of Cr and phosphocreatine (PCr) can be elevated by exogenous Cr. Oral intake of Cr increases the concentration in blood and muscle, and part of the increased muscle Cr is transformed to PCr (a process catalyzed by Cr kinase). Cr supplementation increases total Cr (TCr = Cr + PCr) by \~20%, with the PCr component accounting for 10% of the increase.

Combining HIIT and Cr is intriguing for two reasons; first, Cr supplementation improves performance through increasing PCr, PCr recovery, and muscle buffering which may facilitate higher training intensities and therefore greater training adaptations. Secondly, both Cr and HIIT have individually been shown to increase GLUT 4 and insulin sensitivity, suggesting that Cr supplementation may be an adjunct to HIIT for improving glucose control. To date, there have only been two studies investigating the performance effects of Cr combined with HIIT with preliminary positive results. No studies have examined the impact of combined Cr + HIIT on outcomes related to insulin sensitivity. Therefore, the purpose of this research is to examine the combined effects of Cr and HIIT on performance and insulin sensitivity as determined via an oral glucose tolerance test (OGTT) in young healthy adults.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Creatine

DIETARY_SUPPLEMENT

Placebo

OTHER

High intensity interval training

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-04-30
Completion
2015-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02370212 on ClinicalTrials.gov